Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Oxybutynin | Research

Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis

Authors: Yi Liu, Yanguo Liu, Rongrong Fan, Nurmuhammat Kehriman, Xiaohong Zhang, Bin Zhao, Lin Huang

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Drug repurposing refers to the application of existing drugs to new therapeutic indications. As phenotypic indicators of human drug response, drug side effects may provide direct signals and unique opportunities for drug repurposing.

Objectives

We aimed to identify drugs frequently associated with hypohidrosis or anhidrosis adverse reactions (that is, the opposite condition of hyperhidrosis) from the pharmacovigilance database, which could be potential candidates as anti-hyperhidrosis treatment agents.

Methods

In this observational, retrospective, pharmacovigilance study, adverse event reports of hypohidrosis or anhidrosis in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) were assessed between January 2004 and December 2021 using reporting odds ratio (ROR) estimates and categorized by the World Health Organization Anatomical Therapeutic Chemical (ATC) classification code. The onset time of drug-associated hypohidrosis or anhidrosis was also examined.

Results

There were 540 reports of 192 drugs with suspected drug-associated hypohidrosis or anhidrosis in the FAERS database, of which 39 drugs were found to have statistically significant signals. Nervous system drugs were most frequently reported (187 cases, 55.82%), followed by alimentary tract and metabolism drugs (35 cases, 10.45%), genitourinary system and sex hormones (28 cases, 8.36%), and dermatologicals (22 cases, 6.57%). The top 3 drug subclasses were antiepileptics, drugs for urinary frequency and incontinence, and antidepressants. Taking disproportionality signals, pharmacological characteristics of drugs and appropriate onset time into consideration, the main putative drugs for hyperhidrosis were glycopyrronium, solifenacin, oxybutynin, and botulinum toxin type A. Other drugs, such as topiramate, zonisamide, agalsidase beta, finasteride, metformin, lamotrigine, citalopram, ciprofloxacin, bupropion, duloxetine, aripiprazole, prednisolone, and risperidone need more investigation.

Conclusions

Several candidate agents among hypohidrosis or anhidrosis-related drugs were identified that may be redirected for diminishing sweat production. There are affirmative data for some candidate drugs, and the remaining proposed candidate drugs without already known sweat reduction mechanisms of action should be further explored.
Literature
1.
Wu P, Feng Q, Kerchberger VE, Nelson SD, Chen Q, Li B, et al. Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. Nat Commun. 2022;13(1):46.PubMedPubMedCentralCrossRef
2.
3.
Tanoli Z, Seemab U, Scherer A, Wennerberg K, Tang J, Vähä-Koskela M. Exploration of databases and methods supporting drug repurposing: a comprehensive survey. Brief Bioinform. 2021;22(2):1656–78.PubMedCrossRef
4.
Iwata H, Sawada R, Mizutani S, Yamanishi Y. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data. J Chem Inf Model. 2015;55(2):446–59.PubMedCrossRef
5.
6.
Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415–22.PubMedCrossRef
7.
Hosomi K, Fujimoto M, Ushio K, Mao L, Kato J, Takada M. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLoS ONE. 2018;13(10):e0204648.PubMedPubMedCentralCrossRef
8.
Zaza P, Matthieu R, Jean-Luc C, Charles K. Drug repurposing in Raynaud’s phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2020;86(11):2217–22.PubMedPubMedCentralCrossRef
9.
Chrétien B, Jourdan JP, Davis A, Fedrizzi S, Bureau R, Sassier M, et al. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer’s disease. Br J Clin Pharmacol. 2021;87(7):2830–7.PubMedCrossRef
10.
Wang K, Wan M, Wang RS, Weng Z. Opportunities for web-based drug repositioning: searching for potential antihypertensive agents with hypotension adverse events. J Med Internet Res. 2016;18(4):e76.PubMedPubMedCentralCrossRef
11.
Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, et al. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed Pharmacother. 2022;148:112744.PubMedCrossRef
12.
Kristensen JK, Nielsen C. Progress and lack of progress in hyperhidrosis research 2015–2020. A concise systematic review. Int J Dermatol. 2022;61(2):148–57.PubMedCrossRef
13.
Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51(2):241–8.PubMedCrossRef
14.
Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden: a cross-sectional study in the general population. Dermatology (Basel, Switzerland). 2016;232(5):586–91.PubMedCrossRef
15.
Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS ONE. 2016;11(4):e0153719.PubMedPubMedCentralCrossRef
16.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology (Basel, Switzerland). 2013;227(1):10–3.PubMedCrossRef
17.
Liu Y, Weng W, Tu Y, Wang J. Chinese expert consensus on the surgical treatment of primary palmar hyperhidrosis (2021 version). Chin Med J. 2022;135(11):1264–71.PubMedPubMedCentralCrossRef
18.
Gee S, Yamauchi PS. Nonsurgical management of hyperhidrosis. Thorac Cardiovasc Surg. 2008;18(2):141–55.
19.
Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol. 2019;81(3):669–80.PubMedCrossRef
20.
Pariser DM, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):491–4.PubMedCrossRef
21.
Nawrocki S, Cha J. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82(4):969–79.PubMedCrossRef
22.
Dunford LJ, Radley K, McPhee M, McDonald L, Oliver RJ, Alexandroff A, et al. Setting research priorities for management and treatment of hyperhidrosis: the results of the James Lind Alliance Priority Setting Partnership. Clin Exp Dermatol. 2022;47(6):1109–14.PubMedPubMedCentralCrossRef
23.
24.
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.PubMedPubMedCentralCrossRef
25.
van Puijenbroek EP, van Grootheest K, Diemont WL, Leufkens HG, Egberts AC. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol. 2001;52(5):579–86.PubMedPubMedCentralCrossRef
26.
Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf. 2008;31(2):109–26.PubMedCrossRef
27.
Canel L, Zisimopoulou S, Besson M, Nendaz M. Topiramate-induced severe heatstroke in an adult patient: a case report. J Med Case Rep. 2016;13(10):95.CrossRef
28.
Karachristianou S, Papamichalis E, Sarantopoulos A, Boura P, Georgiadis G. Hypohidrosis induced by topiramate in an adult patient. Epileptic Disord. 2013;15(2):203–6.PubMedCrossRef
29.
Incecik F, Hergüner MO, Altunbaşak S. Hypohidrosis and hyperthermia during topiramate treatment in children. Turk J Pediatr. 2012;54(5):515–8.PubMed
30.
Kim SC, Seol IJ, Kim SJ. Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate. Pediatr Int. 2010;52(1):109–12.PubMedCrossRef
31.
Fung EL, Nelson EA. Oligohydrosis underestimated side effect with topiramate treatment. Indian J Pediatr. 2007;74(7):694.PubMedCrossRef
32.
33.
Kersh AE, Schuchter LM, Elenitsas R, Chu EY. Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy. Immunotherapy. 2020;12(13):951–6.PubMedCrossRef
34.
Liu X, Zhao X, He Y, Tang Y, Yan XL, Zhao B, et al. Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf. 2022;22:1–8.
35.
Böhm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021;87(11):4421–31.PubMedCrossRef
36.
Montastruc JL, Durrieu G. Drug-induced hypohidrosis and anhidrosis: analysis of the WHO pharmacovigilance database 2000–2020. Eur J Clin Pharmacol. 2022;78(5):887–9.PubMedCrossRef
37.
Coon EA, Cheshire WP Jr. Sweating disorders. Continuum (Minneapolis, Minn). 2020;26(1):116–37.PubMed
38.
39.
40.
Leung AK, Cho HY, Choi MC, Chan PY. Hypohidrosis in children. J R Soc Promot Health. 1999;119(2):101–7.PubMedCrossRef
41.
Arcas J, Ferrer T, Roche MC, Martínez-Bermejo A, López-Martín V. Hypohidrosis related to the administration of topiramate to children. Epilepsia. 2001;42(10):1363–5.PubMedCrossRef
42.
Yilmaz K, Tatli B, Yaramiş A, Aydinli N, Calişkan M, Ozmen M. Symptomatic and asymptomatic hypohidrosis in children under topiramate treatment. Turk J Pediatr. 2005;47(4):359–63.PubMed
43.
Cerminara C, Seri S, Bombardieri R, Pinci M, Curatolo P. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol. 2006;34(5):392–4.PubMedCrossRef
44.
Kamikava DYF, Wolosker N, Silva M, Campos JRM, Puech-Leão P. Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin. Clinics (Sao Paulo, Brazil). 2021;76:e2892.PubMedCrossRef
45.
Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016;75(6):1126–33.PubMedCrossRef
46.
Lu BY, Cullen CE, Eide CE, Williams CC, Apfeldorf WJ. Antidepressant-induced sweating alleviated by aripiprazole. J Clin Psychopharmacol. 2008;28(6):710–1.PubMedCrossRef
47.
Huang WL, Chang LR. Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole. Psychiatry Clin Neurosci. 2012;66(3):245.PubMedCrossRef
48.
Maudar V, Winters SJ, Villafuerte BC. Hot flashes and fatigue relieved by metformin. Endocr Pract. 2009;15(1):30–4.PubMedCrossRef
49.
Nath M, Bhattacharjee K, Choudhury Y. Pleiotropic effects of anti-diabetic drugs: a comprehensive review. Eur J Pharmacol. 2020;5(884):173349.CrossRef
50.
Keating GM, Simpson D. Agalsidase Beta: a review of its use in the management of Fabry disease. Drugs. 2007;67(3):435–55.PubMedCrossRef
51.
Briatico G, Pampena R, Fulgione E, Babino G, Giorgio CM, D’Ambra I, et al. Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature. Dermatol Ther. 2021;34(2):e14832.PubMedCrossRef
52.
Wolosker N, Kauffman P, de Campos JRM, Faustino CB, da Silva MFA, Teivelis MP, et al. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. Int J Dermatol. 2020;59(6):709–15.PubMedCrossRef
53.
Almeida ART, Ferrari F, Restrepo MVS, Rocha VB. Oxybutynin in primary hyperhidrosis: a long-term real-life study. Dermatol Ther. 2020;33(6):e14344.PubMedCrossRef
54.
Toledo-Pastrana T, Márquez-Enríquez J, Millán-Cayetano JF. Oral oxybutynin for local and multifocal hyperhidrosis: a multicenter study. Actas Dermo-sifiliograficas. 2017;108(6):597–9.PubMedCrossRef
55.
Campanati A, Gregoriou S, Kontochristopoulos G, Offidani A. Oxybutynin for the treatment of primary hyperhidrosis: current state of the art. Skin Appendage Disord. 2015;1(1):6–13.PubMedPubMedCentralCrossRef
56.
Leow MQH, Tey HL. Treatment of primary palmar hyperhidrosis using glycopyrrolate iontophoresis: Intensity of electrical current used, efficacy and side effects. Indian J Dermatol Venereol Leprol. 2017;83(3):387–8.PubMedCrossRef
57.
Baker DM. Topical glycopyrrolate reduces axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2016;30(12):2131–6.PubMedCrossRef
58.
Hyun MY, Son IP, Lee Y, Choi HG, Park KY, Li K, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–82.PubMedCrossRef
59.
Mackenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol. 2013;169(2):483–4.PubMedCrossRef
60.
McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729–34.PubMed
61.
Campanati A, Martina E, Gregoriou S, Kontochristopoulos G, Paolinelli M, Diotallevi F, et al. Botulinum toxin type A for treatment of forehead hyperhidrosis: multicenter clinical experience and review from literature. Toxins. 2022;14(6):372.PubMedPubMedCentralCrossRef
62.
Yoritaka A, Hishima T, Akagi K, Kishida S. Successful steroid treatment of acquired idiopathic partial hypohidrosis. J Dermatol. 2006;33(4):265–7.PubMedCrossRef
63.
Kobayashi T, Ito T, Kobayashi Y, Mitsuhashi Y, Tsuboi R. Two cases of acquired idiopathic generalized anhidrosis successfully treated by steroid pulse therapy. J Dermatol. 2014;41(5):444–5.PubMedCrossRef
Metadata
Title
Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
Authors
Yi Liu
Yanguo Liu
Rongrong Fan
Nurmuhammat Kehriman
Xiaohong Zhang
Bin Zhao
Lin Huang
Publication date
01-12-2023

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Protective effects of paraoxonase-1, vitamin E and selenium, and oxidative stress index on the susceptibility of low density lipoprotein to oxidation in diabetic patients with/without coronary artery disease

Research

Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer

Research

Bidirectional association between infectious gastroenteritis and inflammatory bowel disease: a population-based study

Research

Comorbidity in patients with Lichen sclerosus: a retrospective cohort study

Research

Primary headache types in adult epilepsy patients

Research

Enhanced activity of the left precuneus as a predictor of visuospatial dysfunction correlates with disease activity in rheumatoid arthritis